Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

User visited derma doctor, suggested finasteride, minoxidil, multivitamins, and PRP therapy. Another user advised against PRP due to cost and ineffectiveness.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

User has hair loss, finasteride for 5 years not effective. Considers trying dutasteride, minoxidil, or pyrilutamide.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

The user has been using finasteride, dutasteride, minoxidil, and a dermaroller/dermastamp for hair loss, reporting positive results and no significant side effects. They switched from finasteride to dutasteride for better results and apply topical minoxidil despite having braids.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

A 22-year-old has been using finasteride and minoxidil for 5 years to combat aggressive male pattern baldness, but is considering switching to dutasteride due to worsening hair loss. Dutasteride is suggested as it may be more effective in reducing DHT levels for aggressive cases.

Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The user experienced significant hair regrowth using topical Minoxidil and Finasteride but had to stop due to high liver enzyme levels. They plan to pause treatment for a month to see if their liver values return to normal.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The conversation discusses experiences with PRP and mesotherapy for hair loss. One user mentions both treatments were costly without significant results.

Bimatoprost was discussed for hair loss, with concerns about long-term scalp effects. A user reported no substantial effect after 6 months of use.